slides · global inventory
Turn
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 37,461
Current window 24,841-24,870
Pages 1,249
Rows per page 30
Beat
24,841-24,870 of 37,461
109
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Satisfaction1 hit
110
The slide uses code snippets as decorative background elements.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Satisfaction1 hit
111
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Satisfaction1 hit
06
The slide uses a three-column layout to present distinct technological approaches.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The chart uses a horizontal bar representation to indicate progress through discovery and IND-enabling stages.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
The slide features a stylized antibody graphic overlaid on a dark blue/purple abstract background.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
The slide uses a structural biology visualization and two dose-response curves to establish bio-equivalence and differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide uses two semi-logarithmic line charts to compare drug concentration decay over time.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
12
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
13
The slide uses a stepped process diagram to illustrate dose escalation cohorts.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
The slide uses a comparative bar chart approach to justify the human half-life prediction based on NHP data.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
Uses icon-based visualization to represent injection frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
16
The slide uses a combination of a pharmacokinetic simulation line chart and a bar chart showing clinical remission rates by exposure quartile.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
The slide uses a timeline-like visual to compare dosing schedules at weeks 0, 2, and 6.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
18
The slide uses a comparative table for safety metrics and a bar chart for ADA rates to establish clinical equivalence/safety.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
19
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
AKT Pictures | Other Presentation Deck | 17 slidesAKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Satisfaction1 hit
16
The timeline uses a diagonal layout with numbered steps.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Satisfaction1 hit
12
Uses a vertical process flow diagram to represent development stage gates.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
13
Uses a before-after-framing style comparison to illustrate the mechanism of action differentiation.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
14
The chart displays longitudinal data for three cell types over 35 days, highlighting the differential pharmacodynamic response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
15
The table uses a structured approach to categorize clinical trials into Foundational, Alternative Dosing, and Registrational enabling.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
16
The slide uses a process flow diagram to illustrate the progression of the clinical trial cohorts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
17
The slide presents clinical trial safety data (ARTISTRY-1) comparing monotherapy and combination therapy cohorts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
18
The slide uses a human body diagram to map clinical responses (CR, PR, uPR) by tumor type and treatment regimen.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
19
Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
20
The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
07
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
08
The chart illustrates the revenue contribution of four specific products (VIVITROL, ARISTADA, VUMERITY, LYBALVI) over time.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit